Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.38 |
| ▸ | F12 | P00748 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 3/20 | 0.32 |
| ▸ | FNTB | P49356 | 2/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | ACACA | Q13085 | 1/20 | 0.32 |
| ▸ | ARG1 | P05089 | 1/20 | 0.32 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24338426 | 0.89 | OTUD7B (0.39) | OTUD7BF12CRBNACACBACACA | |
| SCHEMBL19852885 | 0.84 | OTUD7B (0.36) | OTUD7BF12CRBNACACBACACA | |
| SCHEMBL24339063 | 0.84 | FNTA (0.39) | OTUD7BCRBNFNTAFNTBARG1 | |
| SCHEMBL19852843 | 0.80 | OTUD7B (0.42) | OTUD7BF12CRBNACACBACACA | |
| SCHEMBL24339020 | 0.80 | OTUD7B (0.38) | OTUD7BF12CRBNACACBACACA | |
| SCHEMBL24339056 | 0.78 | OTUD7B (0.42) | OTUD7BF12CRBNACACBACACA | |
| SCHEMBL19851233 | 0.78 | FNTA (0.32) | FNTAFNTBARG1PGGT1B | |
| SCHEMBL17611720 | 0.77 | OTUD7B (0.46) | OTUD7BF12CRBNACACBACACA | |
| SCHEMBL19852842 | 0.76 | OTUD7B (0.45) | OTUD7BF12ACACBACACA | |
| SCHEMBL19852925 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312591-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2023-10-05 | — | — | US | disclosed |
| US-20230312591-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2023-10-05 | — | — | US | disclosed |
| US-11530223-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20220220119-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2022-07-14 | — | — | US | disclosed |
| US-11299495-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2022-04-12 | — | — | US | disclosed |
| WO-2018026779-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC. (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299495-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | OTUD7B 3931/4885F12 4755/4885CRBN 3164/4885 |
| US-11530223-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | OTUD7B 3931/4885F12 4755/4885CRBN 3164/4885 |
| US-20220220119-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | OTUD7B 3931/4885F12 4755/4885CRBN 3164/4885 |
| US-20230312591-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | OTUD7B 3931/4885F12 4755/4885CRBN 3164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.